Director/PDMR Shareholding

RNS Number : 0268Y

Concepta PLC

30 November 2017

 

30 November 2017

Concepta plc

("Concepta" or the "Company")

Director Shareholding

Concepta plc (AIM:CPT), announces that Erik Henau, Chief Executive Officer of the Company, has today purchased 100,000 Ordinary Shares at a price of 7.8 pence per share.

Subsequent to this purchase, Erik Henau is interested in 393,333 Ordinary Shares, representing 0.285% of Concepta's issued ordinary share capital.

The notification below is made in accordance with the requirements of Article 19(3) of the Market Abuse Regulation (EU) No 596/2014.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Erik Henau
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Concepta plc
b)	LEI
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Concepta plc Shares
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) £0.078 100,000
d)	Aggregated information - Aggregated volume - Price
e)	Date of the transaction	30-11-2017
f)	Place of the transaction

Enquiries:

Concepta plc

Adam Reynolds, Chairman

Tel: [phone]

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin / Mark Brady

Tel: [phone]

Novum Securities (Joint Broker)

Colin Rowbury

[phone]

Beaufort Securities Limited (Joint Broker)

Jon Belliss

Tel: [phone]

Yellow Jersey PR Limited (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: [phone]

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

myLotus allows both quantitative and qualitative measurements of a woman's personal hCG and LH hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.  3 cycles of use of myLotus equates to roughly 5% of 1 cycle of IVF.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

END

 

 

DSHWGGCUGUPMGAU